The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Targeting TACE-dependent EGFR ligand shedding in breast cancer
Open accessAbstract
The ability to proliferate independently of signals from other cell types is a fundamental characteristic of tumor cells. Using a 3D culture model of human breast cancer progression, we have delineated a protease-dependent autocrine loop that provides an oncogenic stimulus in the absence of proto-oncogene mutation. Targeting this protease, TNF-alpha-converting enzyme (TACE; also referred to as a disintegrin and metalloproteinase 17 [ADAM17]), with small molecular inhibitors or siRNAs reverted the malignant phenotype in a breast cancer cell line by preventing mobilization of 2 crucial growth factors, TGF-alpha and amphiregulin. We show that TACE-dependent ligand shedding was prevalent in a series of additional breast cancer cell lines and, in all cases examined, was amenable to inhibition. Using existing patient outcome data, we demonstrated a strong correlation between TACE and TGFA expression in human breast cancers that was predictive of poor prognosis. Tumors resulting from inappropriate activation of the EGFR were common in multiple tissues and were, for the most part, refractory to current targeted therapies. The data presented here delineate the molecular mechanism by which constitutive EGFR activity may be achieved in tumor progression without mutation of the EGFR itself or downstream pathway components and suggest that this important oncogenic pathway might usefully be targeted upstream of the receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Cited by
EDWARDS, D., HANDSLEY, M., & PENNINGTON, C. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.001 · Cited by 1,161
Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
Roy, R., Yang, J., & Moses, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5556 · Cited by 854
Nuclear signalling by tumour-associated antigen EpCAM
Maetzel, D., Denzel, S., Mack, B., Canis, M., Went, P., Benk, M., Kieu, C., Papior, P., Baeuerle, P. A., Munz, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1824 · Cited by 719
G protein-coupled receptors: novel targets for drug discovery in cancer
Lappano, R., & Maggiolini, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3320 · Cited by 717
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose-John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683
Modelling breast cancer: one size does not fit all
Vargo-Gogola, T., & Rosen, J. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2193 · Cited by 679
ADAM17: a molecular switch to control inflammation and tissue regeneration
Scheller, J., Chalaris, A., Garbers, C., & Rose-John, S. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.05.005 · Cited by 526
The epidermal growth factor receptor ligands at a glance
Schneider, M. R., & Wolf, E. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21635 · Cited by 447
“An attractive alternative is the inhibition of shedding agents (for instance, ADAM17), a promising strategy once selective inhibitors become available and off-target effects are reduced (Kenny and Bissell, 2007; Merchant et al., 2008).”
BackgroundTIMPs: versatile extracellular regulators in cancer
Jackson, H. W., Defamie, V., Waterhouse, P., & Khokha, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.115 · Cited by 454
The ADAMs: signalling scissors in the tumour microenvironment
Murphy, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2459 · Cited by 451
The tumor microenvironment is a dominant force in multidrug resistance
Correia, A. L., & Bissell, M. J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.006 · Cited by 443
Self-citationZhang, J., Ji, J.-Y., Yu, M., Overholtzer, M., Smolen, G. A., Wang, R., Brugge, J. S., Dyson, N. J., & Haber, D. A. (2009) · Nature Cell Biology · doi:10.1038/ncb1993 · Cited by 424
ADAM-17: the enzyme that does it all
Gooz, M. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409231003628015 · Cited by 377
Tumor-Associated MICA Is Shed by ADAM Proteases
Waldhauer, I., Goehlsdorf, D., Gieseke, F., Weinschenk, T., Wittenbrink, M., Ludwig, A., Stevanovic, S., Rammensee, H.-G., & Steinle, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6768 · Cited by 375
Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease
Chen, J., Zeng, F., Forrester, S. J., Eguchi, S., Zhang, M.-Z., & Harris, R. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00030.2015 · Cited by 327
Metastasis prevention by targeting the dormant niche
Ghajar, C. M. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3910 · Cited by 320
EGFR family: Structure physiology signalling and therapeutic targets †
Burgess, A. W. (2008) · Growth Factors · doi:10.1080/08977190802312844 · Cited by 288
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer
Weigelt, B., & Bissell, M. J. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.013 · Cited by 273
Self-citationTetraspanins Function as Regulators of Cellular Signaling
Termini, C. M., & Gillette, J. M. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00034 · Cited by 266
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer
Rocks, N., Paulissen, G., El Hour, M., Quesada, F., Crahay, C., Gueders, M., Foidart, J. M., Noel, A., & Cataldo, D. (2008) · Biochimie · doi:10.1016/j.biochi.2007.08.008 · Cited by 266
Ectodomain shedding and ADAMs in development
Weber, S., & Saftig, P. (2012) · Development · doi:10.1242/dev.076398 · Cited by 259
Role of ADAMs in Cancer Formation and Progression
Duffy, M. J., McKiernan, E., O'Donovan, N., & McGowan, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1585 · Cited by 259
Xu, P., & Derynck, R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.034 · Cited by 257
The multiple roles of amphiregulin in human cancer
Busser, B., Sancey, L., Brambilla, E., Coll, J.-L., & Hurbin, A. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.05.003 · Cited by 253
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
Lucas, L. M., Dwivedi, V., Senfeld, J. I., Cullum, R. L., Mill, C. P., Piazza, J. T., Bryant, I. N., Cook, L. J., Miller, S. T., Lott, J. H., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000381 · Cited by 70
“…many triple-negative breast tumors (particularly those of the basal-like subtype of triple-negative breast cancer) exhibit elevated expression of EGFR and its ligands (Farnie et al., 2007; Kenny and Bissell, 2007; Gluz et al., 2009; Viale et al., 2009; Burness et al., 2010; Foley et al., 2010).”
BackgroundEffenberger, T., von der Heyde, J., Bartsch, K., Garbers, C., Schulze‐Osthoff, K., Chalaris, A., Murphy, G., Rose‐John, S., & Rabe, B. (2014) · The FASEB Journal · doi:10.1096/fj.14-254565 · Cited by 54
Kenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., Spellman, P. T., Lorenz, K., Lee, E. H., Barcellos-Hoff, M. H., Petersen, O. W., et al. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.02.004 · Cited by 2
Self-citation
Metadata
- Authors
- Kenny, P. A., & Bissell, M. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-02-01
- Volume
- 117
- Issue
- 2
- Pages
- 337-345
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2116561160
- Cited by
- 252
- References
- 44
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.